Expert Discussion: PEGASUS-TIMI 54 - Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label data Live from ESC 2017
ESC Congress 2017, Barcelona
Discussants: Dr. Dominic Angiolillo (Jacksonville, US) & Prof. Christoph Varenhorst (Uppsala, SE)
An expert peer-to-peer discussion on the latest data to come out of the PEGASUS-TIMI 54 trial and its implications for clinical practice.
Dominick J Angiolillo
Dr Dominick Angiolillo graduated from the Catholic University of the Sacred Heart Medical School in Rome, Italy and pursued training in interventional cardiology at the Complutense University of Madrid in Spain and received his Ph.D. in cellular and molecular cardiology. Dr Angiolillo is board-certified in internal medicine, cardiovascular disease and interventional cardiology.
In 2004, Dr Angiolillo joined the University of Florida College of Medicine in Jacksonville, where he is a professor of medicine, director of cardiovascular research and director of the interventional cardiology fellowship program.
Dr Angiolillo has made major scientific contributions to many medical and cardiovascular journals, as well as cardiovascular medicine textbooks. He has authored more than 400 peer-reviewed articles, with nearly 30,000 citations and an H-index of 86. He has authored more than 30 book chapters and is the editor of his own textbook on antithrombotic medicine.
Dr Dominick Angiolillo is on the Editorial Board of European Cardiology Review.
Christoph Varenhorst is associate professor of Cardiology and Senior Consultant Cardiologist at Uppsala University Hospital and Uppsala Clinical Research Center in Uppsala, Sweden. Christoph Varenhorsts research focuses on different aspects of coronary artery disease in both observational real world data sets and experimental clinical trial research.